Disease-related modifications in tau affect the interaction between Fyn and tau

被引:187
作者
Bhaskar, K
Yen, SH
Lee, G
机构
[1] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA
[2] Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA
关键词
D O I
10.1074/jbc.M505895200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Microtubule-associated protein tau is the major component of the neurofibrillary tangles of Alzheimer disease (AD) and is genetically linked to frontotemporal dementias (FTDP-17). We have recently shown that tau interacts with the SH3 domain of Fyn, an Src family non-receptor tyrosine kinase, and is tyrosine-phosphorylated by Fyn on Tyr-18. Also, tyrosine-phosphorylated tau is present in the neuropathology of AD. To determine whether alterations in the tau-Fyn interaction might correlate with disease-related factors in AD and FTDP-17, we have performed real-time surface plasmon resonance studies on a panel of 21 tau constructs with Fyn SH3. We report that the interaction between Fyn SH3 and 3R-tau was 20-fold higher than that with 4R-tau. In addition, the affinity between 4R-tau and Fyn SH3 was increased 25-45-fold by phosphorylation-mimicking mutations or by FTDP-17 mutations. In vitro kinase reactions show that tau, with lower affinity SH3 interactions, exhibited a lower level of Tyr-18 phosphorylation under our reaction conditions. Lastly, we have demonstrated that tau is phosphorylated on Tyr-18 in the tau P301L mouse model for tauopathy (JNPL3). In summary, our results suggest that disease-related phosphorylation and missense mutations of tau increase association of tau with Fyn. Because these effects are mediated through the 4R component of the tau population, these results also have implications for the FTDP-17 diseases caused by increased expression of 4R-tau. Our data support a role for the Fyn-tau interaction in neurodegeneration.
引用
收藏
页码:35119 / 35125
页数:7
相关论文
共 43 条
  • [1] Abraha A, 2000, J CELL SCI, V113, P3737
  • [2] Promotion of hyperphosphorylation by frontotemporal dementia tau mutations
    Alonso, AD
    Mederlyova, A
    Novak, M
    Grundke-Iqbal, I
    Iqbal, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (33) : 34873 - 34881
  • [3] Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease
    Augustinack, JC
    Schneider, A
    Mandelkow, EM
    Hyman, BT
    [J]. ACTA NEUROPATHOLOGICA, 2002, 103 (01) : 26 - 35
  • [4] Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on β-structure in the core domain
    Barghorn, S
    Davies, P
    Mandelkow, E
    [J]. BIOCHEMISTRY, 2004, 43 (06) : 1694 - 1703
  • [5] Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment
    Berry, RW
    Abraha, A
    Lagalwar, S
    LaPointe, N
    Gamblin, TC
    Cryns, VL
    Binder, LI
    [J]. BIOCHEMISTRY, 2003, 42 (27) : 8325 - 8331
  • [6] Tau alteration and neuronal degeneration in tauopathies: mechanisms and models
    Brandt, R
    Hundelt, M
    Shahani, N
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2005, 1739 (2-3): : 331 - 354
  • [7] BRANDT R, 1993, J BIOL CHEM, V268, P3414
  • [8] Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice
    Chin, J
    Palop, JJ
    Yu, GQ
    Kojima, N
    Masliah, E
    Mucke, L
    [J]. JOURNAL OF NEUROSCIENCE, 2004, 24 (19) : 4692 - 4697
  • [9] Regulation of tau isoform expression and dementia
    D'Souza, I
    Schellenberg, GD
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2005, 1739 (2-3): : 104 - 115
  • [10] Dalgarno DC, 1997, BIOPOLYMERS, V43, P383